Elenco degli articoli con argomento «psoriasi»
Dermatologia24 set 2018
Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood
Psoriasis is a chronic immune-mediated disease that represents a unique model for investigating inflammation at local and systemic levels.
24 set 2018
Prurito e rossore della pelle? Può essere psoriasi: i sintomi da non sottovalutare
Milano, 27 giugno 2018 - La psoriasi viene spesso scambiata con altri disturbi della pelle, quali eczema, dermatite, rash cutaneo o una brutta infezione.
24 set 2018
Malattie psoriasiche, la dieta può variare la gravità di presentazione nei pazienti in sovrappeso
Milano, 28 giugno 2018 - La commissione medica della National Psoriasis Foundation raccomanda, in una revisione sistematica della letteratura pubblicata su JAMA Dermatology, la perdita di peso con una dieta ipocalorica per i pazienti sovrappeso e obesi affetti da psoriasi.
24 set 2018
Psoriasi, un caso su tre nei bambini. Conoscerla per diagnosticarla
Milano, 5 luglio 2018 - In circa un terzo dei casi la psoriasi ha esordio in età pediatrica, prevalentemente nelle bambine, tra i 7 e gli 11 anni.
11 set 2018
Topical Janus kinase inhibitors: A review of applications in dermatology
J Am Acad Dermatol. 2018 Sep;79(3):535-544.
04 set 2018
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
04 set 2018
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis FoundationA Systematic Review
25 lug 2018
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation
Expert Opin Biol Ther. 2018 Jul;18(7):727-735. doi: 10.1080/14712598.2018.1481503. Epub 2018 Jun 6.
29 mag 2018
Switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group
Switching is a "hot" topic and the main reasons for switching prior biologic agent are for a primary failure, a secondary failure or drug intolerance, patient's dissatisfaction, physician decision. The aim of the study was to assess the optimization of the switching from a biologic agent to another
15 mag 2018
Buoni risultati per secukinumab contro la psoriasi del cuoio capelluto
L'inibitore dell'interleuchina-17A (IL-17A) secukinumab migliora in maniera significativa la clearance cutanea nei pazienti affetti da psoriasi del cuoio capelluto
07 mag 2018
Cumulative exposure to biologics and risk of cancer in psoriasis patients: A meta-analysis of Psonet studies from Israel, Italy, Spain, UK
Objectives: to assess a dose-response relationship between cumulative length of exposure to biologic therapy and risk of cancer.
29 apr 2018
Corriere.it, la nuova campagna "Chiedi al dermatologo"
La nuova campagna "Chiedi al tuo dermatologo" sul Corriere.it
10 apr 2018
Serum levels of tumor necrosis factor-alpha in patients with psoriasis before, during and after narrow-band UVB phototherapy
We investigate serum levels of tumor necrosis factor-? (TNF-?) in psoriatic patients before and after NB-UVB phototherapy
06 apr 2018
Childhood trauma and resilience in psoriatic patients: A preliminary report
The aim of the study was to investigate childhood trauma and resilience in a psoriatic sample compared with healthy controls. Correlations between childhood trauma, resilience, quality of life, clinical data and psoriatic features were also evaluated
02 apr 2018
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the BADBIR
Serious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox proportional hazards model using data from the BADBIR
20 gen 2018
Association of Psoriasis With Comorbidity Development in Children With Psoriasis
Objective: determine the risk of elevated lipid levels (hyperlipidemia/hypertriglyceridemia), hypertension, metabolic syndrome, polycystic ovarian syndrome, diabetes, nonalcoholic liver disease, and elevated liver enzyme levels in children with and without psoriasis, after accounting for obesity
18 dic 2017
Bambini con psoriasi: farmaci efficaci e con una tossicità accettabile
Quando la malattia è in forma moderata o grave serve una terapia con medicinali. Un'indagine internazionale fa il punto sugli effetti collaterali nei pazienti più piccoli
11 dic 2017
Psoriasi, più rischi per chi ha gran parte della pelle coperta da chiazze
Uno studio Usa sostiene che quanto maggiore è la superficie cutanea interessata, tanto più alto è il pericolo di morire a causa della malattia o di altre patologie collegate
11 dic 2017
Psoriasi a placche, un nuovo farmaco funziona nei malati più gravi
Compare di solito tra i 20 e i 30 anni ed è la forma più comune di questa malattia. Due studi hanno dimostrato l’efficacia di un medicinale biologico, che ha «pulito» la pelle
30 nov 2017
Psoriasis Severity Linked to Increased Risk of Type 2 Diabetes
People with psoriasis have a higher risk of developing type 2 diabetes than those without psoriasis, and the risk increases dramatically based on the severity of the disease, according to a study published in the Journal of the American Academy of Dermatology